Please wait a minute...
浙江大学学报(医学版)  2020, Vol. 49 Issue (3): 340-346    DOI: 10.3785/j.issn.1008-9292.2020.05.02
2019冠状病毒病     
2019冠状病毒病(COVID-19)患者出凝血功能障碍的研究进展
徐亦鸣(),吕丹丹,应可净*()
浙江大学医学院附属邵逸夫医院呼吸内科, 浙江 杭州 310016
Coagulation dysfunction in COVID-19
XU Yiming(),LYU Dandan,YING Kejing*()
Department of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China
 全文: PDF(1035 KB)   HTML( 15 )
摘要:

2019冠状病毒病(COVID-19)患者除常见临床特征之外,还有不同程度的出凝血功能障碍,存在合并血栓和/或出血的风险。COVID-19相关的出凝血功能障碍多为动态过程,可伴有弥散性血管内凝血的形成,与疾病危重程度相关。严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染后所导致的机体免疫炎症反应失衡是患者凝血功能紊乱的重要原因,动态监测、早期防治对于改善患者预后有重大意义。本文就COVID-19患者出凝血功能障碍相关研究进展作一综述,以期为临床研究及决策提供参考。

关键词: 2019冠状病毒病严重急性呼吸综合征冠状病毒2新型冠状病毒肺炎出凝血功能障碍炎症免疫    
Abstract:

In addition to common clinical features, patients with coronavirus disease 2019 (COVID-19) have varying degree of coagulation dysfunction with the risk of thrombosis and/or bleeding. COVID-19 related coagulation dysfunction is a dynamic process, which may be accompanied by the formation of disseminated intravascular coagulation and is related to the severity of the disease. The imbalance of the body's immune and inflammatory response caused by coronavirus infection is an important cause of coagulation dysfunction. Dynamic monitoring as well as early prevention and treatment are of great significance for improving the prognosis of patients. This article reviews the research progress of COVID-19 related coagulation dysfunction, to provide reference for clinical research and management.

Key words: Coronavirus disease 2019    Severe acute respiratory syndrome coronavirus 2    Novel coronavirus pneumonia    Coagulation dysfunction    Inflammation    Immunity
收稿日期: 2020-04-13 出版日期: 2020-06-10
CLC:  R512.99  
基金资助: 国家自然科学基金(81970049)
通讯作者: 应可净     E-mail: 21918273@zju.edu.cn;3197061@zju.edu.cn
作者简介: 徐亦鸣(1996—), 女, 硕士研究生, 主要从事肺血管疾病的基础研究; E-mail:21918273@zju.edu.cn; https://orcid.org/0000-0002-4535-1491
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  
徐亦鸣
吕丹丹
应可净

引用本文:

徐亦鸣,吕丹丹,应可净. 2019冠状病毒病(COVID-19)患者出凝血功能障碍的研究进展[J]. 浙江大学学报(医学版), 2020, 49(3): 340-346.

XU Yiming,LYU Dandan,YING Kejing. Coagulation dysfunction in COVID-19. J Zhejiang Univ (Med Sci), 2020, 49(3): 340-346.

链接本文:

http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.05.02        http://www.zjujournals.com/med/CN/Y2020/V49/I3/340

1 HUANG C , WANG Y , LI X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395 (10223): 497- 506
doi: 10.1016/S0140-6736(20)30183-5
2 WANG D , HU B , HU C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323 (11): 1061- 1069
doi: 10.1001/jama.2020.1585
3 GUAN W J , NI Z Y , HU Y et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382 1708- 1720
doi: 10.1056/NEJMoa2002032
4 ARACHCHILLAGE D , LAFFAN M . Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J]. J Thromb Haemost, 2020, 18 (5): 1233- 1234
doi: 10.1111/jth.14820
5 刘茜, 王荣帅, 屈国强 et al. 新型冠状病毒肺炎死亡尸体系统解剖大体观察报告[J]. 法医学杂志, 2020, 36 (1): 21- 23
LIU Qian , WANG Rongshuai , QU Guoqiang et al. Gross examination report of a COVID-19 death autopsy[J]. Journal of Forensic Medicine, 2020, 36 (1): 21- 23
doi: 10.12116/j.issn.1004-5619.2020.01.005
6 XU Z , SHI L , WANG Y et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8 (4): 420- 422
doi: 10.1016/S2213-2600(20)30076-X
7 CHEN N , ZHOU M , DONG X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:a descriptive study[J]. Lancet, 2020, 395 (10223): 507- 513
doi: 10.1016/S0140-6736(20)30211-7
8 MAO L, WANG M, CHEN S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study[J/OL]. medRxiv, 2020. DOI: 2020.2002.2022.20026500.
9 FOLEY J H , CONWAY E M . Cross talk pathways between coagulation and inflammation[J]. Circ Res, 2016, 118 (9): 1392- 1408
doi: 10.1161/CIRCRESAHA.116.306853
10 IBA T , LEVY J H . Inflammation and thrombosis:roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis[J]. J Thromb Haemost, 2018, 16 (2): 231- 241
doi: 10.1111/jth.13911
11 KAWAI T , AKIRA S . Signaling to NF-κB by Toll-like receptors[J]. Trends Mol Med, 2007, 13 (11): 460- 469
doi: 10.1016/j.molmed.2007.09.002
12 YANG X , LI L , LIU J et al. Extracellular histones induce tissue factor expression in vascular endothelial cells via TLR and activation of NF-κB and AP-1[J]. Thromb Res, 2016, 137 211- 218
doi: 10.1016/j.thromres.2015.10.012
13 SEMERARO F , AMMOLLO C T , MORRISSEY J H et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms:involvement of platelet TLR2 and TLR4[J]. Blood, 2011, 118 (7): 1952- 1961
doi: 10.1182/blood-2011-03-343061
14 KERAGALA C B , DRAXLER D F , MCQUILTEN Z K et al. Haemostasis and innate immunity-a complementary relationship:A review of the intricate relationship between coagulation and complement pathways[J]. Br J Haematol, 2018, 180 (6): 782- 798
doi: 10.1111/bjh.15062
15 ZHOU P , YANG X L , WANG X G et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579 (7798): 270- 273
doi: 10.1038/s41586-020-2012-7
16 WRAPP D , WANG N , CORBETT K S et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020, 367 (6483): 1260- 1263
doi: 10.1126/science.abb2507
17 KUBA K , IMAI Y , OHTO-NAKANISHI T et al. Trilogy of ACE2:a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters[J]. Pharmacol Ther, 2010, 128 (1): 119- 128
doi: 10.1016/j.pharmthera.2010.06.003
18 GLOWACKA I , BERTRAM S , HERZOG P et al. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63[J]. J Virol, 2010, 84 (2): 1198- 1205
doi: 10.1128/JVI.01248-09
19 WANG M, HAO H, LEEPER N J, et al. Thrombotic regulation from the endothelial cell perspectives[J/OL]. Arterioscler Thromb Vasc Biol, 2018, 38(6): e90-e95. DOI: 10.1161/ATVBAHA.118.310367.
20 SODHI C P , WOHLFORD-LENANE C , YAMAGUCHI Y et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration[J]. Am J Physiol Lung Cell Mol Physiol, 2018, 314 (1): L17- L31
doi: 10.1152/ajplung.00498.2016
21 SODHI C P , NGUYEN J , YAMAGUCHI Y et al. A dynamic variation of pulmonary ACE2 is required to modulate neutrophilic inflammation in response to pseudomonas aeruginosa lung infection in mice[J]. J Immunol, 2019, 203 (11): 3000- 3012
doi: 10.4049/jimmunol.1900579
22 VAN DER POLL T , VAN DE VEERDONK F L , SCICLUNA B P et al. The immunopathology of sepsis and potential therapeutic targets[J]. Nat Rev Immunol, 2017, 17 (7): 407- 420
doi: 10.1038/nri.2017.36
23 LEVI M , VAN DER POLL T , BVLLER H R . Bidirectional relation between inflammation and coagulation[J]. Circulation, 2004, 109 (22): 2698- 2704
doi: 10.1161/01.CIR.0000131660.51520.9A
24 MOORE K L , ESMON C T , ESMON N L . Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture[J]. Blood, 1989, 73 (1): 159- 165
doi: 10.1182/blood.V73.1.159.159
25 LEFRAN?AIS E , ORTIZ-MU?OZ G , CAUDRILLIER A et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors[J]. Nature, 2017, 544 (7648): 105- 109
doi: 10.1038/nature21706
26 VARJú I , KOLEV K . Networks that stop the flow:A fresh look at fibrin and neutrophil extracellular traps[J]. Thromb Res, 2019, 182 1- 11
doi: 10.1016/j.thromres.2019.08.003
27 ENGELMANN B , MASSBERG S . Thrombosis as an intravascular effector of innate immunity[J]. Nat Rev Immunol, 2013, 13 (1): 34- 45
doi: 10.1038/nri3345
28 POTZE W , PORTE R J , LISMAN T . Management of coagulation abnormalities in liver disease[J]. Expert Rev Gastroenterol Hepatol, 2015, 9 (1): 103- 114
doi: 10.1586/17474124.2014.934673
29 芦泽源, 王锋, 汪年松 . 抗凝血酶Ⅲ与肾损伤的相关研究进展[J]. 中国中西医结合肾病杂志, 2015, 16 (6): 549- 551
LU Zeyuan , WANG Feng , WANG Niansong . Research progress on antithrombin Ⅲ and kidney damage[J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2015, 16 (6): 549- 551
30 CHIOU H E , LIU C L , BUTTREY M J et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome:experience in two medical centers[J]. Chest, 2005, 128 (1): 263- 272
doi: 10.1378/chest.128.1.263
31 张瑞祺 . α干扰素的血液学不良反应及处理[J]. 肝脏, 2004, S1 36- 39
ZHANG Ruiqi . Hematological side effects and management of αinterferon[J]. Chinese Hepatology, 2004, S1 36- 39
32 DUSHEIKO G . Side effects of alpha interferon in chronic hepatitis C[J]. Hepatology, 1997, 26 (3 Suppl 1): 112S- 121S
doi: 10.1002/hep.510260720
33 THOMAS J , KOSTOUSOV V , TERUYA J . Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation[J]. Semin Thromb Hemost, 2018, 44 (1): 20- 29
doi: 10.1055/s-0037-1606179
34 MURPHY D A , HOCKINGS L E , ANDREWS R K et al. Extracorporeal membrane oxygenation-hemostatic complications[J]. Transfus Med Rev, 2015, 29 (2): 90- 101
doi: 10.1016/j.tmrv.2014.12.001
35 ZHOU F , YU T , DU R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study[J]. Lancet, 2020, 395 (10229): 1054- 1062
doi: 10.1016/S0140-6736(20)30566-3
36 中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组 et al. 新型冠状病毒肺炎相关静脉血栓栓塞症防治建议(试行)[J]. 中华医学杂志, 2020, 100 (11): 808- 813
Pulmonary Embolism and Pulmonary Vascular Disease Group , Chinese Medical Association; Working Committee of Pulmonary Embolism and Pulmonary Vascular Disease , Chinese Medical Doctor Association; National Collaborative Group for Prevention and Treatment of Pulmonary Embolism and Pulmonary Vascular disease et al. Recommendations for prevention and treatment of venous thromboembolism associated with COVID-19(trial)[J]. National Medical Journal of China, 2020, 100 (11): 808- 813
doi: 10.3760/cma.j.cn112137-20200209-00227
37 中国老年医学学会, 国家老年疾病临床医学研究中心(解放军总医院), 解放军老年医学专业委员会 . 感染诱发的老年多器官功能障碍综合征诊断与治疗中国指南2019[J]. 中华老年多器官疾病杂志, 2019, 18 (11): 801- 838
Chinese Society of Geriatrics , National Clinical Medical Research Center for Geriatrics (PLA general hospital) , PLA Geriatrics Professional Committee . 2019 China guidelines for diagnosis and treatment of infection-induced multiorgan dysfunction syndrome in the elderly[J]. Chinese Journal of Multiple Organ Diseases in the Elderly, 2019, 18 (11): 801- 838
doi: 10.11915/j.issn.1671-5403.2019.11.174
38 中华医学会血液学分会血栓与止血学组 . 弥散性血管内凝血诊断中国专家共识(2017年版)[J]. 中华血液学杂志, 2017, 38 (5): 361- 363
Thrombosis and Hemostasis Group, Hematology Society of Chinese Medical Association . Consensus of Chinese experts on diagnosis of disseminated intravascular coagulation (version 2017)[J]. Chinese Journal of Hematology, 2017, 38 (5): 361- 363
doi: 10.3760/cma.j.issn.0253-2727.2017.05.001
39 高倩, 甄凯元, 刘鹏 et al. 关注新型冠状病毒肺炎相关静脉血栓栓塞症的预防和诊治——《新型冠状病毒肺炎相关静脉血栓栓塞症防治建议(试行)》解读[J]. 中华普通外科杂志, 2020, 35 (3): 259- 262
GAO Qian , ZHEN Kaiyuan , LIU Peng et al. Focus on the prevention and treatment of venous thromboembolism related to COVID-19-interpretation of recommendations for prevention and treatment of COVID-19-related venous thromboembolism (trial)[J]. Chinese Journal of General Surgery, 2020, 35 (3): 259- 262
doi: 10.3760/cma.j.cn113855-20200220-00101
[1] 何叶艳,郑婵颖. 三种人类高致病性冠状病毒的增殖和传播机制研究进展[J]. 浙江大学学报(医学版), 2020, 49(3): 324-339.
[2] 伦永志,刘奔,董雯,孙杰,潘凌鸿. 两种严重急性呼吸综合征冠状病毒S蛋白结构特征及抗原表位比较[J]. 浙江大学学报(医学版), 2020, 49(3): 315-323.
[3] 胡燕, 李晓峰, 龚卫月. 2019冠状病毒病(COVID-19)危重型患者的营养支持治疗[J]. 浙江大学学报(医学版), 2020, 49(3): 347-355.
[4] 陈志敏,傅君芬,舒强,汪伟,陈英虎,华春珍,李甫棒,林茹,唐兰芳,汪天林,王颖硕,徐玮泽,杨子浩,叶盛,袁天明,张晨美,张园园. 儿童2019冠状病毒病(COVID-19)诊疗指南(第二版)[J]. 浙江大学学报(医学版), 2020, 49(2): 139-146.
[5] 徐凯进,蔡洪流,沈毅弘,倪勤,陈瑜,胡少华,李剑平,王华芬,俞亮,黄河,裘云庆,魏国庆,方强,周建英,盛吉芳,梁廷波,李兰娟. 2019冠状病毒病(COVID-19)诊疗浙江经验[J]. 浙江大学学报(医学版), 2020, 49(2): 147-157.
[6] 姜赛平,李璐,茹仁萍,张春红,饶跃峰,林彬,王融溶,陈娜,王小娟,蔡洪流,盛吉芳,周建英,卢晓阳,裘云庆. 2019冠状病毒病(COVID-19)重型、危重型患者用药管理经验[J]. 浙江大学学报(医学版), 2020, 49(2): 158-169.
[7] 李鑫,代甜,王虹,石军年,袁薇,栗静,陈利军,张天明,张珊珊,孔焱,岳宁,时慧,何玉苹,胡惠芳,柳芙蓉,杨彩霞. 2019冠状病毒病(COVID-19)疑似患者合并焦虑和抑郁的临床分析[J]. 浙江大学学报(医学版), 2020, 49(2): 203-208.
[8] 骆嵩,杨丽娟,王春,刘传苗,李殿明. 血浆置换和托珠单抗治疗六例2019冠状病毒病(COVID-19)重型患者临床分析[J]. 浙江大学学报(医学版), 2020, 49(2): 227-231.
[9] 洪东升,倪剑,单文雅,李璐,胡希,羊红玉,赵青威,张幸国. 基于监测数据的药物不良反应快速识别及R语言实现[J]. 浙江大学学报(医学版), 2020, 49(2): 253-259.
[10] 钟琦,李志,沈晓勇,徐凯进,沈毅弘,方强,陈峰,梁廷波. 2019冠状病毒病(COVID-19)不同临床分型患者胸部CT影像学特征[J]. 浙江大学学报(医学版), 2020, 49(2): 198-202.
[11] 康仙慧,张荣,何慧梁,姚永兴,郑跃英,温小红,祝胜美. 一例妊娠合并2019冠状病毒病(COVID-19)患者的剖宫产麻醉管理[J]. 浙江大学学报(医学版), 2020, 49(2): 249-252.
[12] 陈旭,李央,王金希,蔡洪流,曹红翠,盛吉芳. 三例妊娠合并2019冠状病毒病(COVID-19)患者诊治分析[J]. 浙江大学学报(医学版), 2020, 49(2): 240-244.
[13] 沈利华,黄菲,陈祥,熊钻,杨晓玉,李慧,程丰,郭健,龚国富. 严重急性呼吸综合征冠状病毒2(SARS-CoV-2)核酸检测试剂盒临床诊断效能评估[J]. 浙江大学学报(医学版), 2020, 49(2): 185-190.
[14] 张胜,李丹萍,陈华忠,郑丹,周益萍,陈葆国,石卫武,林荣海. 糖皮质激素治疗一例2019冠状病毒病(COVID-19)危重型患者炎症反应动态观察[J]. 浙江大学学报(医学版), 2020, 49(2): 220-226.
[15] 李游江,胡瑛瑛,张晓东,喻员员,李斌,吴建国,吴英萍,夏肖萍,徐键. 七例2019冠状病毒病(COVID-19)普通型患者出院后病毒核酸随访结果[J]. 浙江大学学报(医学版), 2020, 49(2): 270-274.